Quick Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Receptors activated | GLP-1 receptor only | GIP receptor and GLP-1 receptor |
| Brand names (diabetes) | Ozempic, Rybelsus (oral) | Mounjaro |
| Brand names (weight management) | Wegovy | Zepbound |
| FDA status | FDA-approved prescription medication | FDA-approved prescription medication |
| Head-to-head weight loss | Reference comparator in SURMOUNT-5 | Greater average weight loss in SURMOUNT-5 |
What Each Medication Is
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It's FDA-approved under the brand names Ozempic and Rybelsus (the oral tablet version) for type 2 diabetes, and under the brand name Wegovy for chronic weight management. It was the first medication in this class to reach wide use for weight loss and remains one of the most recognized names in the category.
Tirzepatide is a dual GIP/GLP-1 (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1) receptor agonist, meaning it activates two different incretin receptor pathways rather than one. It's FDA-approved under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for chronic weight management.
Both are prescription medications, not research chemicals or over-the-counter supplements. That distinction matters more here than with most of the peptides covered elsewhere on this site, since Semaglutide and Tirzepatide have gone through the full FDA drug-approval process and require a prescription from a licensed healthcare provider.
Mechanism: One Receptor vs Two
This is the core distinction between the two drugs. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GIP receptor and the GLP-1 receptor, making it a dual-agonist rather than a single-agonist medication. Both receptor pathways sit within the same incretin system, the set of gut hormones that respond to food intake and help regulate blood sugar and appetite.
In practical terms, both medications work by slowing gastric emptying, increasing feelings of fullness after eating, and improving insulin secretion in response to meals. That shared mechanism is why both are used for type 2 diabetes management and for chronic weight management, even though they were developed and approved under different brand names for each use case.
Why the second receptor matters: adding GIP receptor activity alongside GLP-1 receptor activity is the mechanistic rationale behind Tirzepatide, and it's the reason the two drugs are studied and marketed as distinct medications rather than as interchangeable versions of the same drug.
Human Evidence: The Head-to-Head Trial
A head-to-head clinical trial, SURMOUNT-5, directly compared tirzepatide and semaglutide for weight management in the same study population. That trial found tirzepatide produced greater average weight loss than semaglutide over the course of the study. This is one of the few direct comparisons in the category, since most of the earlier evidence for each drug came from separate trials against placebo rather than against each other.
A head-to-head result at the group level doesn't mean every individual will respond the same way. Response to either medication varies from person to person, and a prescribing provider is best positioned to weigh trial evidence against a specific person's health history and goals.
Regulatory Status and Safety
Both Semaglutide and Tirzepatide are FDA-approved prescription medications. They are not sold as research chemicals, and they should never be sourced outside a licensed pharmacy with a valid prescription from a healthcare provider. This puts them in a different regulatory category than most of the peptides discussed elsewhere on this site, many of which are sold as research chemicals without FDA approval for human use. Starting, adjusting, or stopping either medication should happen under medical supervision.
Common side effects for both are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose escalation, when the dose is being gradually increased toward a maintenance level, and tend to ease over time as the body adjusts.
What They Have in Common, and What's Different
In common: both are incretin-based medications that slow gastric emptying, increase satiety, and improve meal-time insulin secretion. Both are FDA-approved for type 2 diabetes under one brand name and for chronic weight management under a separate brand name. Both share a similar gastrointestinal side effect profile, most noticeable during dose escalation.
Different: Semaglutide activates a single receptor (GLP-1), while Tirzepatide activates two (GIP and GLP-1). In the one available head-to-head trial, Tirzepatide showed greater average weight loss. The two also come in different brand-name and formulation options, including Semaglutide's oral tablet version (Rybelsus), which Tirzepatide does not currently have.
Bloodwork to Track
Fasting glucose and HbA1c both reflect blood sugar control and are useful for tracking either medication's effect over time; see how the two markers relate in the fasting glucose vs HbA1c comparison. Fasting insulin reflects insulin sensitivity, which often improves alongside weight loss on either drug. A lipid panel is also worth tracking, since metabolic improvements from either medication frequently show up in cholesterol and triglyceride markers as well. See the full peptide bloodwork guide for the rest of the core panel.
Choosing Between Them
This isn't a decision to make alone. Semaglutide and Tirzepatide are both FDA-approved prescription medications, and choosing between them, including dose, formulation, and whether either is appropriate at all, is a conversation to have with a prescribing healthcare provider who knows a person's full medical history. What this comparison can offer is context going into that conversation: the mechanistic difference between a single-receptor and dual-receptor medication, and what the available head-to-head evidence shows. BioStackIQ's Fat Loss Calculator can help frame realistic expectations around a weight management goal, and Rate My Stack can help evaluate how a broader protocol fits together once a direction is set with a provider.